PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-173639 | Others
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Pharmacogenomics technology&therapeutic diagnosis/concomitant diagnosis (CDx) Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET
7.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PHARMACOGENOMICS TECHNOLOGY&THERAPEUTIC DIAGNOSIS/CONCOMITANT DIAGNOSIS (CDX) MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Foundation Medicine
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 GE Healthcare
16.3 Leica Biosystems Nussloch GmBH
16.4 Pfizer
16.5 F Hoffman La Roche
16.6 Thermo Fisher Scientific Inc
16.7 Qiagen NV
16.8 Agilent Technologies
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Major Types CoveredOther types
sequence
Immunohistochemistry
In situ hybridization
Polymerase chain reaction (PCR)
Major Downstream Industry Covered
Oncology Department
Immune diseases
Neurological disorders
Other uses
Cardiovascular disease
Companies
Foundation Medicine
GE Healthcare
Leica Biosystems Nussloch GmBH
Pfizer
F Hoffman La Roche
Thermo Fisher Scientific Inc
Qiagen NV
Agilent Technologies
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.